ALICIA (Acalabrutinib in CLL Therapy)
← catalyst calendarSponsored by AstraZeneca (industry) · AZN — their whole pipeline →.
Phase
—
Status
Completed
Study type
Observational
Enrollment
90actual
Sites
15
Country
Russia
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2021-02-03 | actual | When the study began enrolling |
| Primary completion | 2026-02-28 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-02-28 | actual | The whole study's end, after follow-up |
| First posted | 2021-02-10 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-17 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Chronic Lymphocytic Leukemia
Primary outcomes
what the primary-completion date above is the date OF• progression-free survival (rwPFS) in patients with CLL who are treated with acalabrutinib in clinical practice in Russia
measured Up to 2 years
• incidence of adverse events and serious adverse events in CLL patients treated with acalabrutinib in clinical practice in Russia
measured Up to 2 years
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed